Kimryn Rathmell

Kimryn Rathmell: New drug type in the kidney cancer space and the value of rare disease research

Kimryn Rathmell, Director of 

“I’m excited to see that the discovery of a drug to target HIF-2alpha, first developed for a rare disease (VHL syndrome), is now making a difference in common kidney cancers. This adds a new drug type in the kidney cancer space and highlights the value of rare disease research.”

Source: Kimryn Rathmell/X

cancer HIF-2alpha kidney cancer Kimryn Rathmell National Cancer Institute NCI OncoDaily Oncology rare disease research VHL syndrome Von Hippel-Lindau disease